276 related articles for article (PubMed ID: 29725256)
1. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
Dong L; Lin F; Wu W; Liu Y; Huang W
Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
[TBL] [Abstract][Full Text] [Related]
2. Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway.
Li T; Guo T; Liu H; Jiang H; Wang Y
Oncol Rep; 2021 Jan; 45(1):83-94. PubMed ID: 33416116
[TBL] [Abstract][Full Text] [Related]
3. Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway.
Gibault F; Bailly F; Corvaisier M; Coevoet M; Huet G; Melnyk P; Cotelle P
ChemMedChem; 2017 Jun; 12(12):954-961. PubMed ID: 28334506
[TBL] [Abstract][Full Text] [Related]
4. YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.
Hua G; Lv X; He C; Remmenga SW; Rodabough KJ; Dong J; Yang L; Lele SM; Yang P; Zhou J; Karst A; Drapkin RI; Davis JS; Wang C
Oncogene; 2016 Apr; 35(17):2247-65. PubMed ID: 26364602
[TBL] [Abstract][Full Text] [Related]
5. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo.
Li H; Huang Z; Gao M; Huang N; Luo Z; Shen H; Wang X; Wang T; Hu J; Feng W
J Exp Clin Cancer Res; 2016 Sep; 35(1):134. PubMed ID: 27599610
[TBL] [Abstract][Full Text] [Related]
8. Hippo signaling promotes JNK-dependent cell migration.
Ma X; Wang H; Ji J; Xu W; Sun Y; Li W; Zhang X; Chen J; Xue L
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1934-1939. PubMed ID: 28174264
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.
Guillemette S; Rico C; Godin P; Boerboom D; Paquet M
J Mammary Gland Biol Neoplasia; 2017 Sep; 22(3):203-214. PubMed ID: 28822004
[TBL] [Abstract][Full Text] [Related]
10. Targeting YAP in malignant pleural mesothelioma.
Zhang WQ; Dai YY; Hsu PC; Wang H; Cheng L; Yang YL; Wang YC; Xu ZD; Liu S; Chan G; Hu B; Li H; Jablons DM; You L
J Cell Mol Med; 2017 Nov; 21(11):2663-2676. PubMed ID: 28470935
[TBL] [Abstract][Full Text] [Related]
11. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression.
Pan W; Wang Q; Zhang Y; Zhang N; Qin J; Li W; Wang J; Wu F; Cao L; Xu G
Cell Physiol Biochem; 2016; 39(2):481-90. PubMed ID: 27383277
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor.
Sebio A; Lenz HJ
Clin Cancer Res; 2015 Nov; 21(22):5002-7. PubMed ID: 26384319
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma.
Zhao F; Yang Z; Chen Y; Zhou Q; Zhang J; Liu J; Wang B; He Q; Zhang L; Yu Y; Liu P
World Neurosurg; 2018 Sep; 117():e269-e279. PubMed ID: 29902598
[TBL] [Abstract][Full Text] [Related]
14. Verteporfin inhibits growth of human glioma in vitro without light activation.
Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
[TBL] [Abstract][Full Text] [Related]
15. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer.
Shen J; Cao B; Wang Y; Ma C; Zeng Z; Liu L; Li X; Tao D; Gong J; Xie D
J Exp Clin Cancer Res; 2018 Jul; 37(1):175. PubMed ID: 30055645
[TBL] [Abstract][Full Text] [Related]
16. Regulation of YAP by mechanical strain through Jnk and Hippo signaling.
Codelia VA; Sun G; Irvine KD
Curr Biol; 2014 Sep; 24(17):2012-7. PubMed ID: 25127217
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional cofactor Mask2 is required for YAP-induced cell growth and migration in bladder cancer cell.
Dong L; Lin F; Wu W; Huang W; Cai Z
J Cancer; 2016; 7(14):2132-2138. PubMed ID: 27877230
[TBL] [Abstract][Full Text] [Related]
18. PTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesis.
Xu W; Yang Z; Xie C; Zhu Y; Shu X; Zhang Z; Li N; Chai N; Zhang S; Wu K; Nie Y; Lu N
J Exp Clin Cancer Res; 2018 Aug; 37(1):198. PubMed ID: 30134988
[TBL] [Abstract][Full Text] [Related]
19. YAP activation is an early event and a potential therapeutic target in liver cancer development.
Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
[TBL] [Abstract][Full Text] [Related]
20. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]